Return
Checkpoint Blockade
DOI:10.1158/2643-3230.BCD-21-0130.png)
Abstract
En 中文
An emerging strategy to enhance the efficacy of immune checkpoint blockade in relapsed/refractory cancers is increasing immunogenic cell death via combination with cytotoxic therapies. Understanding the effects of cytotoxic and immunotherapeutic agents on immune cell populations will enable improved mechanism-based design of combination therapies to maximum efficacy and minimum toxicity.
Journal
IF:
11.5
Papers:
216
Citations:
1.7K
Organization
Cited Papers
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
LEUKEMIA
IF13.4
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML
BLOOD ADVANCES
IF7.1
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
BLOOD CANCER DISCOVERY
IF11.5
no more

